Compare Cytokinetics Inc (CYTK) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares China Large-Cap ETF — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B). The key difference: Cytokinetics Inc is far larger — about 2.2× iShares China Large-Cap ETF's market cap, and iShares China Large-Cap ETF is more actively traded (16,526,479 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares China Large-Cap ETF for 149 Days on average.
| CYTK | FXI | |
|---|---|---|
Market Cap | $8.62B | $3.90B |
Volume | 2,594,626 | 16,526,479 |
Sector | Health | — |
52-Week High | $87.26 | $41.08 |
52-Week Low | $54.76 | $31.59 |
Typical Hold Time | 19 Days | 149 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
FXI (iShares China Large-Cap ETF) trades at $33.42, down 1.04% with a bearish technical outlook. The ETF shows compelling valuation at half the S&P 500's P/E ratio with a 1.98% yield, but faces headwinds from China's economic challenges and geopolitical tensions. Recent corporate profit growth of 26% in Q2 2026 provides fundamental support, though weak momentum persists amid global trade concerns.
The ETF offers diversification value and valuation appeal but carries significant political and economic risks. China's industrial overcapacity and weak domestic consumption create volatility, while U.S.-China relations remain a key variable. Institutional interest focuses on long-term value despite near-term bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
